share_log

A股CRO概念异动拉升,谱尼测试涨近5%,太龙药业、未名医药、泓博医药、海特生物、蔚蓝生物等跟涨

The A-share CRO concept changed and increased, with Punitest rising by nearly 5%, while Tailong Pharmaceutical, Hongbo Pharmaceutical, Haite Biotech, and Blue Biotech followed suit

Zhitong Finance ·  Apr 11 10:17
The A-share CRO concept changed and increased, with Punitest rising by nearly 5%, while Tailong Pharmaceutical, Hongbo Pharmaceutical, Haite Biotech, and Blue Biotech followed suit

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment